Myriad Genetics (NASDAQ:MYGN) Azioni

MYRIAD GENETICS INC

Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Myriad Genetics Inc

WIIM

MYGN

Myriad Genetics shares are trading higher. The company announced early access to FirstGene Multiple Prenatal Screen.

Myriad Genetics shares are trading higher after the company announced new data from its MONSTAR-SCREEN 3 study.

<a href="https://www.globenewswire.com/Tracker?data=t6BzLIYkM2Titjo2engsbYdYzVAKdATUpngXwVnOZLIFJeWOfs8JrzmA569pg5PP_wzcfVu2vxAkFgwTviT40sMP1XwBJn9-iup44hY2Ll8=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise&#x2122; MRD Test to detect and monitor ctDNA in patients.
The interim results – first shared at the <a href="https://www.globenewswire.com/Tracker?data=BdItqSDA6Al6o-I38SIC8HVerhVbF4nmX3ccqI_QUByE92yXbvem_fZDt7OQiI8cB2NKQK4abOO6M6jL-D0tMte8h9L5gZyDFjQTEqQDUNNJPBB4ksABOeMgezfAqA3z09nF2QurM9LI5SGkqo5aWA==">2025 ASCO Annual Meeting</a> by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood. Key findings include:
<ul>
<li>Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested.</li>
<li>Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.</li>
<li>Clearance of ctDNA during neoadjuvant chemotherapy, as shown by Precise MRD, predicted pathological complete response. &nbsp;</li>
</ul>
"Previous studies have shown that ctDNA-based MRD detection significantly correlates with recurrence risk and predicts benefit of adjuvant chemotherapy in certain cancers," said Takayuki Yoshino, MD, PhD of the NCCHE and principal investigator for the MONSTAR-SCREEN-3 study. "However, first-generation MRD assays appear to have limited sensitivity in low ctDNA-shedding tumors. For our pan-cancer study, we selected Precise MRD because of its enhanced sensitivity across diverse tumor types."
"Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests," said Dr. Hashimoto. "In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection."
"The initial results from the study highlight the tremendous potential for utilizing Precise MRD across cancer types to enhance personalized treatment and therapeutic strategies for patients," said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. "Precise MRD is informed by WGS, enabling the tracking of thousands of tumor-specific sites, far more than what is possible with first-generation MRD tests. Tracking so many variants yields exceptional sensitivity even in cancers with low shedding tumors such as breast and renal. A key benefit of our ultrasensitive assay is confidence in ctDNA results, as shown by the finding that the ctDNA status after neoadjuvant treatment was strongly associated with pathological response."

News

Myriad Genetics Announces MONSTAR-SCREEN 3 Data, Advancing Pan-Cancer MRD Testing

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Compass Point analyst Casey Alexander downgraded the rating for PennantPark Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) from Neutral to Sell and lowered the price target from $6 to $5.75. Pennant Park Investment shares closed at $6.91 on Tuesday. <a href="https://www.benzinga.com/quote/pnnt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Sidharth Sahoo downgraded UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Hold to Reduce and lowered the price target from $490 to $270. UnitedHealth shares closed at $321.58 on Tuesday. <a href="https://www.benzinga.com/quote/unh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Sung Ji Nam downgraded the rating for Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Sector Outperform to Sector Perform and cut the price target from $20 to $6. Myriad Genetics shares closed at $4.45 on Tuesday. <a href="https://www.benzinga.com/quote/mygn/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UNH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21092954/image-265-1024x586.png" alt="" class="wp-image-922875" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21092954/image-265-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21092954/image-265-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21092954/image-265-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21092954/image-265.png 1045w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45535402/target-lowes-and-3-stocks-to-watch-heading-into-wednesday">Target, Lowe&#8217;s And 3 Stocks To Watch Heading Into Wednesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Analyst Ratings

Trading Ideas

PNNT

This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday

Scotiabank analyst Sung Ji Nam downgrades Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Sector Outperform to Sector Perform and lowers the price target from $20 to $6.

Price Target

Scotiabank Downgrades Myriad Genetics to Sector Perform, Lowers Price Target to $6

U.S. stocks were lower, with the Nasdaq Composite falling around 50 points on Monday.
Shares of CI&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) rose sharply during <a href="https://www.benzinga.com/quote/CINT/analyst-ratings">Monday's session</a>.
JP Morgan analyst Puneet Jain upgraded CI&amp;T from Neutral to Overweight and announced a $7 price target.
CI&amp;T shares jumped 8.2% to $6.60 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares jumped 50% to $2.8050.</li>
<li>TMC the metals company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NYSE">TMC</a>) gained 18% to $4.3150. TMC Metals, last week, posted a first-quarter loss of 6 cents per share.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 15.5% to $7.77 after the company provided FY25, 2026, and 2027 R&amp;D and SG&amp;A expense guidance. The FDA gave its conditional approval to its COVID-19 vaccine, targeting specific populations under particular conditions.</li>
<li>Paramount Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGRE#NYSE">PGRE</a>) gained 15% to $5.50. Paramount Group announced strategic alternatives review to maximize shareholder value.</li>
<li>Ruanyun Edai Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) climbed 12.7% to $11.36.</li>
<li>New Fortress Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>) rose 11.8% to $2.9750.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) gained 9.7% to $20.12 following better-than-expected first-quarter results.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 9% to $7.99.</li>
<li>Avino Silver &amp; Gold Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASM#NYSE">ASM</a>) rose 8.2% to $2.8906.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) surged 6.9% to $4.4150.</li>
<li>BGC Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGC#NYSE">BGC</a>) gained 6.8% to $9.85. BGC repurchased 16,452,850 from Commerce Secretary Lutnick as Lutnick divests interests pursuant to US government ethics rules.</li>
<li>Ryanair Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>) rose 6.1% to $53.06.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Intraday Update

Movers

CINT

NVAX

NWTN

PGRE

RYAAY

RYET

CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday

Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Overweight and lowers the price target from $12.5 to $9.

Piper Sandler Maintains Overweight on Myriad Genetics, Lowers Price Target to $9

Wells Fargo analyst Brandon Couillard downgrades Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Overweight to Equal-Weight and lowers the price target from $22 to $6.

Wells Fargo Downgrades Myriad Genetics to Equal-Weight, Lowers Price Target to $6

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.36, a high estimate of $29.00, and a low estimate of $7.00. A decline of 17.71% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655260_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Myriad Genetics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Myriad Genetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Key Indicators: Myriad Genetics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.12% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Myriad Genetics Stock

Biotech

General

Myriad Genetics Publishes RiskScore Study In JCO Precision Oncology

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 25.4% to $189.28 during Wednesday's regular session. The company's market cap stands at $2.4 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock increased by 23.37% to $0.4. The company's market cap stands at $4.3 million. </li>
<li>Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) stock moved upwards by 20.66% to $11.47. The market value of their outstanding shares is at $5.6 billion. The company's, Q1 earnings came out today. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) shares moved upwards by 19.47% to $13.56. The market value of their outstanding shares is at $587.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock rose 18.02% to $2.03. The company's market cap stands at $9.6 million. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 17.77% to $69.94. The market value of their outstanding shares is at $8.6 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.6% to $0.09 during Wednesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock fell 41.43% to $0.8. The company's market cap stands at $2.2 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 36.46% to $4.62. The company's market cap stands at $425.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 29.61% to $1.07. The company's market cap stands at $2.8 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 26.03% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock decreased by 24.03% to $3.39. The market value of their outstanding shares is at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

ELAN

HALO

HEPA

KTTA

PHIO

TOVX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Goldman Sachs analyst Matthew Sykes maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy and lowers the price target from $14 to $8.

Goldman Sachs Maintains Buy on Myriad Genetics, Lowers Price Target to $8

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Wednesday.
The Dow traded up 0.64% to 41,090.68 while the NASDAQ fell 0.20% to 17,655.00. The S&amp;P 500 also rose, gaining, 0.20% to 5,618.00.
Check This Out: <a href="https://www.benzinga.com/25/05/45251087/robinhood-zscaler-palo-alto-and-a-real-estate-stock-on-cnbcs-final-trades">Robinhood, Zscaler, Palo Alto And A Real Estate Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.2% on Wednesday.
In trading on Wednesday, materials stocks fell by 0.6%.
Top Headline
Uber Technologies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) reported weaker-than-expected revenue for the first quarter on Wednesday.
The company reported a quarterly revenue growth of 14% year-on-year to $11.53 billion, missing the analyst consensus estimate of $11.62 billion. Uber reported adjusted EPS of 83 cents, which beat the analyst consensus estimate of 50 cents.
Gross Bookings grew 14% Y/Y to $42.82 billion. Uber expects fiscal second-quarter 2025 gross bookings of $45.75 billion-$47.25 billion and adjusted EBITDA of $2.02 billion-$2.12 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares shot up 265% to $2.25 after the company announced it entered into a merger agreement with Strive Asset Management to be the first publicly traded asset management bitcoin treasury company.</li>
<li>Shares of Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) got a boost, surging 51% to $9.56 following a first-quarter revenue and EPS beat. Additionally, the company raised its FY25 sales guidance above estimates.</li>
<li>CuriosityStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) shares were also up, gaining 52% to $5.02 after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) shares dropped 35% to $4.70 after the company reported a first-quarter sales miss and cut its FY25 guidance below estimates.</li>
<li>Shares of Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) were down 62% to $0.1427 after the company announced it voluntarily delisted from the Nasdaq.</li>
<li>The Hain Celestial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) was down, falling 49% to $1.40 after the company reported worse-than-expected third-quarter results, guided for a 5%-6% YoY decline in FY25 organic net sales, announced the departure of its CEO and said its board hired Goldman Sachs for a portfolio review.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $58.50 while gold traded down 0.7% at $3,399.30.
Silver traded down 1.1% to $33.030 on Wednesday, while copper fell 2.6% to $4.6560.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.48%, while Spain's IBEX 35 Index fell 0.43%. Germany's DAX 40 fell 0.36% and France's CAC 40 fell 0.88% during the session.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.14%, Hong Kong's Hang Seng Index gaining 0.13%, China's Shanghai Composite Index rising 0.80% and India's BSE Sensex gaining 0.13%.
Economics
U.S. mortgage application volumes climbed by 11% from the previous week during the week ending May 2.
The EIA reported that crude oil inventories in the U.S. declined by 2.032 million barrels in the week ended May 2, compared to market estimates of a 1.7 million barrel fall.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

ASST

CURI

HAIN

PRCH

UBER

VSTE

Crude Oil Falls 1%; Uber Sales Miss Estimates

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $16 to $7.

UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $7

Raymond James analyst Andrew Cooper reiterates Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Outperform and lowers the price target from $19 to $10.

Reiteration

Raymond James Reiterates Outperform on Myriad Genetics, Lowers Price Target to $10

Myriad Genetics shares are trading lower following worse-than-expected Q1 sales results and after the company lowered its FY25 guidance below estimates.

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 88.9% to $2.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 45.13% to $0.8. The company's market cap stands at $2.8 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares moved upwards by 21.56% to $140.3. The company's market cap stands at $7.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares rose 21.09% to $22.11. The market value of their outstanding shares is at $389.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 19.56% to $3.85. The market value of their outstanding shares is at $21.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 17.68% to $0.56. The company's market cap stands at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 55.0% to $0.08 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 24.35% to $5.5. The company's market cap stands at $506.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 20.22% to $0.75. The company's market cap stands at $2.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 18.08% to $38.3. The company's market cap stands at $3.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock decreased by 14.41% to $1.13. The market value of their outstanding shares is at $719.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares fell 12.54% to $91.7. The company's market cap stands at $6.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GERN

KZIA

LNTH

RIGL

SRPT

ZVSA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares rose 15.1% to $3.66 during Tuesday's after-market session. The company's market cap stands at $19.5 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares increased by 11.11% to $4.9. The market value of their outstanding shares is at $68.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares moved upwards by 10.89% to $20.25. The market value of their outstanding shares is at $356.7 million. The company's, Q1 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) stock moved upwards by 10.0% to $0.33. The company's market cap stands at $14.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 9.84% to $0.42. The company's market cap stands at $11.8 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 9.35% to $0.49. The market value of their outstanding shares is at $71.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 20.7% to $37.0 during Tuesday's after-market session. The company's market cap stands at $3.6 billion. The company's, Q1 earnings came out today. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 18.44% to $5.93. The company's market cap stands at $546.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 16.87% to $0.78. The market value of their outstanding shares is at $3.0 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock fell 8.82% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 8.49% to $1.51. The market value of their outstanding shares is at $2.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 8.48% to $1.08. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDSX

CPIX

EVOK

HBIO

LPCN

ONMD

THAR

12 Health Care Stocks Moving In Tuesday's After-Market Session

Myriad Genetics shares are trading lower after the company reported a Q1 sales miss and cut its FY25 guidance below estimates.

Guidance

Myriad Genetics Lowers FY2025 Adj EPS Guidance from $0.07-$0.11 to $(0.02)-$0.02 vs $0.08 Est; Lowers FY2025 Sales Guidance from $840.00M-$860.00M to $807.00M-$823.00M vs $844.87M Est

Press Releases

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Earnings

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Penny Stocks

Small Cap

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Health Care

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Scotiabank

Piper Sandler

Wells Fargo

Goldman Sachs

Comments

Myriad Genetics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO